Last reviewed · How we verify

NCT06160115

The Role of NK Cells to Detect Blood Infection in ALL.

Status unknown Last updated 7 December 2023
What this trial tests

trial testing Flow cytometry in Acute Lymphoblastic Leukemia in 56 participants. Status unknown.

Timeline
1 February 2024
Primary endpoint
1 February 2025
1 April 2025

Quick facts

Lead sponsorAssiut University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment56
Start date1 February 2024
Primary completion1 February 2025
Estimated completion1 April 2025

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 0 to 17, any sex, with Acute Lymphoblastic Leukemia or Bloodstream Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. Assess possibility of prediction of blood stream infections in ALL patients by profiling of NK cells using flow cytometry. 2. Assess the role of NK cells in development of drug resistance post chemotherapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Flow cytometry

Trials testing the same drug.

Other recruiting trials for Acute Lymphoblastic Leukemia

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06160115.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing